Search Results

You are looking at 11 - 20 of 294 items for :

  • "Neoadjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices

Neelima Denduluri, Debra A. Patt, Yunfei Wang, Menaka Bhor, Xiaoyan Li, Anne M. Favret, Phuong Khanh Morrow, Richard L. Barron, Lina Asmar, Shanmugapriya Saravanan, Yanli Li, Jacob Garcia, and Gary H. Lyman

relative to standard chemotherapy regimens among 16,233 patients with 6 tumor types who were treated with adjuvant or neoadjuvant chemotherapy regimens currently in widespread use in community oncology practices in the United States. Methods Data

Full access

HSR19-106: Association Between Pathological Complete Responses and Long-Term Survival Outcomes Among Triple-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Cynthia Z. Qi, Min Huang, Amin Haiderali, Jipan Xie, Zheng-Yi Zhou, Eric Q. Wu, and Peter Fasching

cohort studies and recent clinical trials in the literature. Methods: English publications reporting association between pCR and survival outcomes among TNBC patients receiving neoadjuvant chemotherapy were searched in MEDLINE, EMBASE, Cochrane CENTRAL

Full access

HSR21-072: Neoadjuvant Chemotherapy in Breast Cancer Care: Does Equal Access Mitigate Racial Disparities?

Shannon Ugarte, Annie Tang, Zhonet Harper, Rohan E. John, Kala Mehta, Amal Khoury, and Kevin Knopf

To review racial differences in a safety net hospital in pathologic complete response (pCR) rate and outcome of neoadjuvant chemotherapy (NACT) for invasive breast cancer at a safety-net hospital. This is a retrospective cohort study of women

Full access

Optimizing Systemic Therapy for Bladder Cancer

Sumanta K. Pal, Matthew I. Milowsky, and Elizabeth R. Plimack

systemic treatments for bladder cancer. 7 Because of the already broad scope of this review, combined modality treatment (ie, chemoradiation) is not discussed. Neoadjuvant Chemotherapy For nonmetastatic, muscle-invasive bladder cancer (MIBC) staged

Full access

CLO23-050: Total Neoadjuvant Chemotherapy Followed by HIPEC and Curative Surgery in Treatment of Locally Advanced Gastric Cancer

Veronika Patsko, Oleksii Dobrzhankiy, and Yurii Kondratsky

patients showed cytologically positive peritoneal lavage. Each patient received 8 cycles of neoadjuvant chemotherapy (FLOT) followed by a total gastrectomy with D2 lymphadenectomy and HIPEC. Agents used for HIPEC: mitomycin 15 mg/m2 and cisplatin 75 mg/m2

Full access

Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer

Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz

statistically significant rate of increased pathCR, or improvement in rates of failure-free or overall survivals, when comparing neoadjuvant chemotherapy followed by chemoradiotherapy and then surgery and adjuvant chemotherapy versus chemoradiotherapy followed

Full access

CLO24-074: Impact of Neoadjuvant Chemotherapy on Survival and Pathological Response Among Octogenarians Who Underwent Radical Cystectomy for Muscle-Invasive Bladder Cancer

Arjun Pon Avudaiappan, Pushan Prabhakar, Ahmed Eldefrawy, Jorge Caso, and Murugesan Manoharan

Introduction: Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) represents the standardized treatment approach for muscle-invasive bladder cancer (MIBC). With improvements in healthcare, many octogenarians are undergoing major

Full access

Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II–III Breast Cancer: A Multicenter Value Analysis

Colby J. Hyland, Flora Varghese, Christina Yau, Heather Beckwith, Katia Khoury, William Varnado, Gillian L. Hirst, Robert R. Flavell, A. Jo Chien, Douglas Yee, Claudine J. Isaacs, Andres Forero-Torres, Laura J. Esserman, and Michelle E. Melisko

nodules, and enlarged and/or hypermetabolic lymph nodes (not including the axilla or internal mammary chains). Time to initiation of neoadjuvant chemotherapy was the number of days between the date of core biopsy–proved cancer diagnosis and the date that

Full access

Treating Elderly Patients With Muscle-Invasive Bladder Cancer

Elizabeth R. Kessler, Janet B. Kukreja, Christopher L. Geiger, and Stacy M. Fischer

assessment of a patient's functional age and longevity can help direct more appropriate treatment on an individual basis. Figure 1. Algorithm for treatment of muscle-invasive bladder cancer in elderly patients. Abbreviations: NAC, neoadjuvant chemotherapy; RT

Full access

Use and Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer: A Population-Based Study

Christopher M. Booth, Sulaiman Nanji, Xuejiao Wei, Yingwei Peng, James J. Biagi, Timothy P. Hanna, Monika K. Krzyzanowska, and William J. Mackillop

Identification of study population. Abbreviation: NACT, neoadjuvant chemotherapy. did not differ substantially from those of the 18,094 unselected cases ( see supplemental eTable 1 and eFigure 1, available with this article at JNCCN.org ). Among the 7